



Please complete ALL information below and fax your request to 1-888-671-5285

Kadian® (morphine extended-release [ER] capsule)
Long-Acting Opioid Prior Authorization Request Form (Page 1 of 3)
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required) and Provider Information (required) form with fields for Member Name, Insurance ID#, Date of Birth, Street Address, City, State, Zip, Phone, Provider Name, NPI#, Specialty, Office Phone, Office Fax, Office Street Address, City, State, Zip.

Medication Information (required) form with fields for Medication Name, Strength, Dosage Form, and checkboxes for generic substitution and continuation of therapy.

Clinical Information (required) form with sections for terminal illness mandate, continuation of therapy, and applicable diagnoses.

For diagnosis of moderate to severe chronic pain that is non-neuropathic, please answer the following: Is the prescribed medication being used as an as-needed (PRN) analgesic? Is the prescribed medication being used for pain that is mild or not expected to persist for an extended period of time? Is the prescribed medication being used for acute pain? Is the prescribed medication being used for postoperative pain? Has the patient already received chronic opioid therapy prior to surgery or is the postoperative pain expected to be moderate to severe and persist for an extended period of time? Is the patient filling the prescribed medication for the first time? Prior to the start of therapy with the prescribed medication, has the patient failed an adequate trial of a short-acting opioid? If yes, please document the name of the medication(s), dose, date, and duration of trial: Medication: Dose: Date of trial: Duration of trial:

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of FutureScripts. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately. Office use only: Kadian-MorphineER\_FSP\_2018Nov-W



**Kadian<sup>®</sup> (morphine extended-release [ER] capsule)**  
**Long-Acting Opioid Prior Authorization Request Form (Page 2 of 3)**

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

**For diagnosis of moderate to severe neuropathic pain or fibromyalgia, please answer the following:**

Does the patient have a contraindication to or has not exhibited an adequate response to treatment with gabapentin titrated to a therapeutic dose?  **Yes**  **No** If **yes**, please document dose, date, and duration of trial:

Dose: \_\_\_\_\_ Date of trial: \_\_\_\_\_ Duration of trial: \_\_\_\_\_

Does the patient have a contraindication to or has not exhibited an adequate response to treatment with a tricyclic antidepressant titrated to a therapeutic dose?  **Yes**  **No** If **yes**, please document the name of the medication(s), dose, date, and duration of trial:

Medication: \_\_\_\_\_ Dose: \_\_\_\_\_ Date of trial: \_\_\_\_\_ Duration of trial: \_\_\_\_\_

Is the patient filling the prescribed medication for the first time?  **Yes**  **No**

Prior to the start of therapy with the prescribed medication, has the patient failed an adequate trial of a short-acting opioid?  **Yes**  **No**

If **yes**, please document the name of the medication(s), dose, date, and duration of trial:

Medication: \_\_\_\_\_ Dose: \_\_\_\_\_ Date of trial: \_\_\_\_\_ Duration of trial: \_\_\_\_\_

**Select the medications the patient has a trial and failure, contraindication, or intolerance to:**

- Embeda (morphine sulfate and naltrexone hydrochloride)
- Hydromorphone ER
- Hysingla ER
- Morphine sulfate ER
- Oxycontin (oxycodone hydrochloride)
- Oxymorphone ER

**Reauthorization [Non-cancer and non-end of life care only]:**

**If this is a reauthorization request, please answer all of the following questions:**

1. What are the treatment goals for this patient? (Document treatment goals and estimated duration of treatment) \_\_\_\_\_
2. Does the treatment plan include the use of a non-opioid analgesic and/or non-pharmacologic intervention?  **Yes**  **No**
3. Has the patient demonstrated meaningful improvement in pain and function using a validated instrument (e.g., Brief Pain Inventory)?  **Yes**  **No**
4. Has the patient been screened for substance abuse/opioid dependence using a validated instrument (e.g., DAST-10)?  **Yes**  **No**
5. What is the rationale for not tapering and discontinuing the requested medication? (Document rationale) \_\_\_\_\_
6. Has the patient been screened for comorbid mental health conditions?  **Yes**  **No**
7. Is there a state prescription drug monitoring program (PDMP) available?  **Yes**  **No**  
If **yes**, has the prescriber identified that there are **NO** concurrently prescribed controlled substances from the PDMP?  **Yes**  **No**
8. Does the prescriber acknowledge that he/she has completed an assessment of increased risk for respiratory depression in patients who have medical comorbidities or are using concurrent benzodiazepine/other drugs that could potentially cause drug-drug interactions?  **Yes**  **No**
9. What is the patient's total daily morphine equivalent dose? \_\_\_\_\_

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of FutureScripts. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Kadian-MorphineER\_FSP\_2018Nov-W



**Kadian<sup>®</sup> (morphine extended-release [ER] capsule)  
 Long-Acting Opioid Prior Authorization Request Form (Page 3 of 3)**  
 DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

**Quantity limit requests:**

What is the quantity requested per DAY? \_\_\_\_\_

Does the patient's diagnosis include malignant (cancer) pain?  Yes  No

Was the requested medication prescribed by a pain specialist or by pain management consultation?  Yes  No

**Select all of the following that have been maintained and documented in chart notes\*:**

- A description of the nature and intensity of the pain
- An appropriate patient medical history and physical examination
- An updated, comprehensive treatment plan (the treatment plan should state objectives that will be used to determine treatment success, such as pain relief or improved physical and/or psychosocial function)
- Appropriate dose escalation
- Ongoing, periodic review of the course of opioid therapy
- Verification that the risks and benefits of the use of the requested medication have been discussed with the patient, significant other(s), and/or guardian

**\*Chart documentation:**

Will chart documentation be submitted with this form, confirming the above information?  Yes  No

*\*\*Please note: Chart documentation of the above is required to be submitted along with this fax form.*

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

---



---

Please note: This request may be denied unless all required information is received.